Nanotechnology offers some of its greatest potential contributions in the precise control of molecular binding events and the transduction of binding phenomena. My lab is committed to employing this potential for two crucial pursuits: the early detection of cancer, and the innovative treatment of metastatic disease.
Daniel A. Heller, PhD
Research FocusChemist Daniel Heller focuses on biomaterials and nanoscale engineering for molecular sensors and targeted therapeutics.
- PhD, University of Illinois at Urbana-Champaign
- A Schroeder, DA Heller, MM Winslow, JE Dahlman, GW Pratt, R Langer, T Jacks, DG Anderson: “Treating metastatic cancer with nanotechnology.” Nature Reviews Cancer 12 (2012) 39-50.
- J Budhathoki-Uprety, PV Jena, D Roxbury, DA Heller: “Helical Polycarbodiimide Cloaking of Carbon Nanotubes Enables Inter-Nanotube Exciton Energy Transfer Modulation.” Journal of the American Chemical Society (2014) In Press.
- NIH Director’s New Innovator Award (2012)
- Damon Runyon Cancer Research Foundation Postdoctoral Fellowship (2010)
- Beckman Institute Graduate Fellowship (2006)